Shachar Tauber, MD
Ophthalmology · Springfield, MONPI 1174689723
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 51.5% of the total. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $471.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$77K
- Sun Pharmaceutical Industries Inc.$36K
- Glaukos Corporation$19K
- Shire North American Group Inc$8K
- Apellis Pharmaceuticals, Inc.$2K
- Dompe US, Inc.$1K
- plus $7K from 22 others
Across 35 payments — averaging $3264.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$45K
- Novartis$25K
- Shire North American Group Inc$22K
- Kowa Research Institute, Inc.$17K
- AbbVie$5K
What the payments were for
- Consulting fees$87,96159%
- Speaking & faculty fees$40,37527%
- Travel & lodging$5,8854%
- Food & beverage$16,08511%
- Entertainment$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 151 | $77,424 |
| Sun Pharmaceutical Industries Inc. | 32 | $35,854 |
| Glaukos Corporation | 48 | $18,982 |
| Shire North American Group Inc | 8 | $8,105 |
| Apellis Pharmaceuticals, Inc. | 1 | $1,633 |
| Dompe US, Inc. | 4 | $1,371 |
| Kala Pharmaceuticals, Inc. | 1 | $1,300 |
| Aerie Pharmaceuticals, Inc. | 2 | $710 |
| Rxsight Inc | 9 | $689 |
| Carl Zeiss Meditec, Inc. | 7 | $675 |
| Carl Zeiss Meditec USA, Inc. | 11 | $605 |
| AbbVie(2 entities) | 13 | $596 |
| Harrow Eye, LLC | 5 | $375 |
| Novartis | 3 | $301 |
| Bausch & Lomb Americas Inc. | 5 | $255 |
| Oyster Point Pharma, Inc. | 2 | $251 |
| Johnson & Johnson Vision Care, Inc. | 1 | $171 |
| Sight Sciences, Inc. | 1 | $146 |
| Lensar, Inc. | 2 | $140 |
| Genmab U.S., Inc. | 1 | $125 |
| Staar Surgical Company | 3 | $120 |
| Alcon | 2 | $118 |
| Eyevance Pharmaceuticals LLC | 1 | $115 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Biosense Webster, Inc. | 2 | $64 |
| Ocular Therapeutix, Inc. | 1 | $59 |
| Tearlab Corp | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$35,446
- Compact Intuitiv$33,581
- Whitestar Phaco Handpiece$30,206
- Baerveldt Glaucoma Implant (250)$29,531
- Catalys Laser System$19,526
- COMPACT INTUITIV Phacofragmentation System$19,422
- Baerveldt Glaucoma Implants$13,347
- Compound/Component$13,347
- Tecnis Multifocal Family of 1-piece IOLS$10,917
- Tecnis Symfony IOL$10,800
- Tecnis Toric 1-piece IOL$10,125
- Epioxa$8,516
- CATALYS SYSTEM$8,327
- XIIDRA$8,280
- Tecnis 1-piece IOL$4,050
- Tecnis 3-piece IOL$3,375
- Tecnis Symphony IOL$3,375
- Tecnis Symphony Toric IOL$3,375
- CE-marked KXLA system$2,800
- Tecnis IOL$2,394
How this compares
$150,320 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 16 | $677,278 |
| RestasisCyclosporine | 223 | $205,011 |
| TyrvayaVarenicline Tartrate | 44 | $28,176 |
| VevyeCyclosporine | 35 | $26,011 |
| MieboPerfluorohexyloctane/Pf | 32 | $25,858 |
| Cyclosporine | 44 | $22,048 |
| Loteprednol Etabonate | 115 | $16,624 |
| XiidraLifitegrast | 18 | $13,805 |
| LotemaxLoteprednol Etabonate | 35 | $10,848 |
| EysuvisLoteprednol Etabonate | 18 | $10,715 |
| RhopressaNetarsudil Mesylate | 30 | $10,631 |
| Lotemax SmLoteprednol Etabonate | 35 | $9,052 |
| InveltysLoteprednol Etabonate | 14 | $7,120 |
| Prednisolone Acetate | 281 | $7,011 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $5,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $1,371 | $677,27816 claims |
| AbbVieRestasis | $596 | $205,011223 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $255 | $39,66450 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax, Lotemax Sm | $100 | $36,524185 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $251 | $28,17644 claims |
| Harrow Eye, LLCVevye | $375 | $26,01135 claims |
| Kala Pharmaceuticals, Inc.Eysuvis, Inveltys | $1,300 | $17,83432 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $710 | $16,44246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Springfield
- Wendell ScottSpringfield$42K
- Thomas PraterSpringfield$30K
- Jacob ThomasSpringfield$6K
- Lucas LenciSpringfield$6K
- Daniel OsbornSpringfield$5K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.